Getting to 95-95-95: global use of HIV generics would result in large reductions in spending, new infections and deaths
Australian clinicians discuss challenges of delivering PrEP in new study
Testing homeless people during COVID-19 identifies several new HIV cases, especially in Black people
‘Resilient’ HIV programmes in African countries have maintained viral suppression during the COVID-19 pandemic
To be cost-effective, injectable PrEP can only cost about $3000 more than US generic oral PrEP
South Africans continued to receive ART during COVID-19 lockdown, but HIV testing and starting ART were impeded
European HIV doctors conduct their first-ever region-wide audit of services
European AIDS Treatment Group documents the impact of COVID on HIV services throughout Europe
Survey shows the impact of COVID-19 lockdown on LGBT communities
